Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy.
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Phosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1 gene. The clinical phenotype is characterized by protein-losing enteropathy, while neurological manifestations prevailing in other types of CDGS are absent. Using standard diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (phosphomannomutase deficiency). Daily oral mannose administration is a successful therapy for this new type of CDG syndrome classified as CDGS type Ib.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phosphomannomutase deficiency is a cause of carbohydrate‐deficient glycoprotein syndrome type I
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)01357-1 · Cited by 359 · cited 6×
“ing to a procedure by van Schaftingen and Jaeken (6).”
BackgroundMethodInfluentialJaeken, J., Vanderschueren-Lodeweyckx, M., Casaer, P., Snoeck, L., Corbeel, L., Eggermont, E., & Eeckels, R. (1980) · Pediatric Research · doi:10.1203/00006450-198002000-00117 · Cited by 287 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Panneerselvam, K., & Freeze, H. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118570 · Cited by 146 · cited 1×
“Based on studies showing that mannose could correct abnormal glycosylation in CDGS type Ia fibroblasts (15), mannose therapy was initiated and followed up for 11 mo.”
BackgroundSelf-citationThe X-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 Å resolution
Cleasby, A., Wonacott, A. J., Skarzynski, T. J., Hubbard, R. E., Davies, G. J., Proudfoot, A. E. I., Bernard, A. R., Payton, M. A., & Wells, T. N. C. (1996) · Nature Structural Biology · doi:10.1038/nsb0596-470 · Cited by 115
Alton, G., Kjærgaard, S., Etchison, J. R., Skovby, F., & Freeze, H. H. (1997) · Biochemical and Molecular Medicine · doi:10.1006/bmme.1997.2574 · Cited by 111 · cited 1×
“In accordance with previous human ingestion studies (19), mannose was given orally in an initial dose of 100 mg/kg body wt three times a day.”
Self-citationCarbohydrate-Deficient Glycoprotein Syndrome - A Fourth Subtype
Stibler, H., Stephani, U., & Kutsch, U. (1995) · Neuropediatrics · doi:10.1055/s-2007-979762 · Cited by 92 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Purification cDNA cloning and heterologous expression of human phosphomannose isomerase
PROUDFOOT, A. E. I., TURCATTI, G., WELLS, T. N. C., PAYTON, M. A., & SMITH, D. J. (1994) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1994.tb19954.x · Cited by 86 · cited 3×
“The sequence of the human PMI cDNA (10) was used to design primers for PCR amplification.”
BackgroundMethodInfluentialCarbohydrate-Deficient Glycoprotein (CDG) Syndrome - A New Variant, Type III
Stibler, H., Westerberg, B., Hanefeld, F. A., & Hagberg, B. (1993) · Neuropediatrics · doi:10.1055/s-2008-1071513 · Cited by 71 · cited 1×
“(1) Hexokinase; (2) glucose 6-phosphate dehydrogenase; (3) phosphoglucose isomerase; (4) phosphomannose isomerase; (5) phosphomannomutase; (6) GDPmannose synthase.”
Human Fibroblasts Prefer Mannose over Glucose as a Source of Mannose for N-Glycosylation
Panneerselvam, K., Etchison, J. R., & Freeze, H. H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23123 · Cited by 70
Self-citationA novel Saccharomyces cerevisiae secretory mutant possesses a thermolabile phosphomannose isomerase
Payton, M. A., Rheinnecker, M., Klig, L. S., Detiani, M., & Bowden, E. (1991) · Journal of Bacteriology · doi:10.1128/jb.173.6.2006-2010.1991 · Cited by 70 · cited 1×
“Phenotypic correction of the PMI deficiency in yeast was achieved by supplying 5 mM mannose together with glucose (20).”
Method
Cited by
Items 201–300 of 427
Go, S., Sato, C., Furuhata, K., & Kitajima, K. (2006) · Glycoconjugate Journal · doi:10.1007/s10719-006-6734-z · Cited by 29
Lehrman, M. A. (2006) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409230500542575 · Cited by 27
“The metabolic basis for hypoglycosylation in Types Ib and Ic appears to be reasonably well understood, based upon [2-3H]mannose labeling studies (Niehues et al., 1998; Körner et al., 1998) and by FACE (Gao et al., 2005).”
MethodTherapeutic Monosaccharides: Looking Back, Moving Forward
Sosicka, P., Ng, B. G., & Freeze, H. H. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00565 · Cited by 28
Self-citationMetformin-stimulated Mannose Transport in Dermal Fibroblasts
Shang, J., & Lehrman, M. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310837200 · Cited by 27
Schroeder, A. S., Kappler, M., Bonfert, M. V., Borggraefe, I., Schoen, C., & Reiter, K. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9252-x · Cited by 24
“The reported patient was the index patient in whom a new type of CDG with prominent gastrointestinal involvement and excellent response to oral mannose supplementation was discovered [then designated CDG Ib (Niehues et al. 1998), recently renamed MPI-CDG].”
BackgroundInfluentialSelf-citationHimmelreich, N., Dimitrov, B., Geiger, V., Zielonka, M., Hutter, A., Beedgen, L., Hüllen, A., Breuer, M., Peters, V., Thiemann, K. C., et al. (2019) · Human Mutation · doi:10.1002/humu.23764 · Cited by 24
de Koning, T. J., DORLAND, L., & Henegouwen, G. P. V. B. (1999) · Journal of Hepatology · doi:10.1016/s0168-8278(99)80052-x · Cited by 24
Witters, P., Edmondson, A. C., Lam, C. T., Johnsen, C., Patterson, M. C., Raymond, K., He, M., Freeze, H. H., & Morava, É. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01751-2 · Cited by 23
“Priorities for advancing a therapy for PMM2‐CDG Historically there was initial enthusiasm for mannose supplementation in PMM2-CDG given dramatic improvement in MPI-CDG with mannose supplementation [5] and biochemical correction with mannose in PMM2-CDG patient-derived fibroblasts [6].”
BackgroundSelf-citationTherapies and therapeutic approaches in Congenital Disorders of Glycosylation
Thiel, C., & Körner, C. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9447-5 · Cited by 24
Self-citationScreening for congenital disorders of glycosylation in the first weeks of life
Thiel, C., Meßner‐Schmitt, D., Hoffmann, G. F., & Körner, C. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9531-9 · Cited by 23
Self-citationDiversity of congenital disorders of glycosylation
Leonard, J. V., Grünewald, S., & Clayton, P. T. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04618-3 · Cited by 23
D-mannose: a Novel Prognostic Biomarker for Patients with Esophageal Adenocarcinoma
Gu, J. H., Liang, D., Pierzynski, J. A., Leizhen, Z., Ye, Y., Zhang, J., Ajani, J. A., & Wu, X. (2017) · Carcinogenesis · doi:10.1093/carcin/bgw207 · Cited by 22
“Previous research has mostly focused on d-mannose for the treatment of glycosylation deficiency caused by genetic defects in phosphomannose isomerase (27) and the prevention of urinary tract infections by blocking the adhesion of Escherichia coli to uroepithelial cells (28).”
MethodDietary mannose supplementation in phosphomannomutase 2 deficiency (PMM2-CDG)
Taday, R., Grüneberg, M., Chesne, I. D., Reunert, J., & Marquardt, T. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01528-z · Cited by 25
“Even in MPI-CDG, the �rst partial corrections in IEF-and SDS-patterns of serum transferrin needed several to occur after initiation of a mannose therapy with a dose of 100mg/kg three times a day [5].”
BackgroundInfluentialSelf-citationMolecular cloning, gene organization, and expression of mouse Mpi encoding phosphomannose isomerase
Davis, J. A., Wu, X., Wang, L., DeRossi, C., Westphal, V., Wu, R., Alton, G., Srikrishna, G., & Freeze, H. H. (2002) · Glycobiology · doi:10.1093/glycob/cwf060 · Cited by 22
“Mutations in human MPI cause congenital disorder of glycosylation type Ib (OMIM 602579) and result in inefficient glycosylation due to a limited amount of precursors (Niehues et al., 1998).”
BackgroundSelf-citationNews on Clinical Details and Treatment in PGM1-CDG
Schrapers, E., Tegtmeyer, L. C., Ŝimić-Schleicher, G., Debus, V., Reunert, J., Balbach, S. T., Klingel, K., Chesne, I. D., Seelhöfer, A., Fobker, M., et al. (2015) · JIMD Reports · doi:10.1007/8904_2015_471 · Cited by 21
Self-citationNakouzi, G. A., Kreidieh, K., & Yazbek, S. N. (2014) · Journal of Community Genetics · doi:10.1007/s12687-014-0203-3 · Cited by 21
Takahashi, T., Honda, R., & Nishikawa, Y. (2000) · Glycobiology · doi:10.1093/glycob/10.3.321 · Cited by 21
“A deficiency of the enzyme phosphomannose isomerase has also been demonstrated to be responsible for patients showing a CDGS type I phenotype (CDGS type Ib) (de Koning et al., 1998; Niehues et al., 1998).”
BackgroundHuman Glycosylation Disorders and Sugar Supplement Therapy
Freeze, H. H. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9945 · Cited by 22
Self-citationBudhraja, R., Radenkovic, S., Jain, A., Muffels, I. J. J., Ismaili, M. H. A., Kozicz, T., Pandey, A., & Morava, É. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108487 · Cited by 20
Mechanisms of Liver Injury Relevant to Pediatric Hepatology
Tanner, M. S. (2002) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408360290795439 · Cited by 20
D-mannose transport and metabolism in isolated enterocytes
Duran, J. M., Cano, M., Rubio, M. J. P., & Ilundáin, A. A. (2004) · Glycobiology · doi:10.1093/glycob/cwh059 · Cited by 22
“These values are within the range of values (8±34 nmol/mg protein min) reported for mouse intestine (Davis and Freeze, 2001), human fibroblasts, and leucocytes (Niehues et al., 1998; Westphal et al., 2001) and validate the PMI activity measurements reported here.”
Resultde Loos, F., Huijben, K., van de Kar, N. C. A. J., Monnens, L. A. H., van den Heuvel, L. P., Groener, J. E. M., de Moor, R. A., & Wevers, R. A. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.5.781 · Cited by 20
Acarregui, M. J., George, T. N., & Rhead, W. J. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70115-5 · Cited by 20
Guerbet glycolipids from mannose: liquid crystals properties
Patrick, M., Zahid, N. I., Kriechbaum, M., & Hashim, R. (2018) · Liquid Crystals · doi:10.1080/02678292.2018.1492036 · Cited by 19
“from the aldohexose series and is a C-2 epimer of glucose [9] with a small structural difference – the hydroxyl group is at the ring C-2 position axial instead of equatorial (in glucose), but the physical behaviours of mannose differ from those of glucose [10].”
BackgroundMPI-CDG with transient hypoglycosylation and antithrombin deficiency
de la Morena‐Barrio, M. E., Wypasek, E., Owczarek, D., Miñano, A., Vicente, V., Corral, J., & Undas, A. (2018) · Haematologica · doi:10.3324/haematol.2018.211326 · Cited by 19
“In all these MPI-CDG patients, daily oral mannose administration turned out to be successful therapy, which corrected the biochemical phenotype although never reaching normal values, and significantly improved clinical signs.(13,15,16) In the current proband and her brother, one might expect at least similar clinical…”
BackgroundInfluentialCongenital disorders of glycosylation: Have you encountered them?
Westphal, V., Srikrishna, G., & Freeze, H. H. (2000) · Genetics in Medicine · doi:10.1097/00125817-200011000-00005 · Cited by 19
Self-citationApproaches to homozygosity mapping and exome sequencing for the identification of novel types of CDG
Matthijs, G., Rymen, D., Millón, M. B. B., Souche, E. L., & Race, V. (2012) · Glycoconjugate Journal · doi:10.1007/s10719-012-9445-7 · Cited by 21
“[13–17, 19–48, 53–76] 72 Glycoconj J (2013) 30:67–76”
Unsuccessful intravenous D-mannose treatment in PMM2-CDG
Grünert, S. C., Marquardt, T., Lausch, E. U., Fuchs, H. W., Thiel, C., Sutter, M., Schumann, A., Hannibal, L., & Spiekerkoetter, U. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1213-3 · Cited by 21
Self-citationN‐glycome analysis detects dysglycosylation missed by conventional methods in SLC39A8 deficiency
Park, J. H., Mealer, R. G., Elias, A. F., Hoffmann, S., Grüneberg, M., Biskup, S., Fobker, M., Haven, J., Mangels, U., Reunert, J., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12306 · Cited by 21
Self-citationLexikon der Syndrome und Fehlbildungen
Witköwski, R., Prokop, O., & Ullrich, E. (1999) · Springer eBooks · doi:10.1007/978-3-642-98007-7_6 · Cited by 17
Congenital disorders of glycosylation: narration of a story through its patents
Monticelli, M., D’Onofrio, T., Jaeken, J., Morava, É., Andreotti, G., & Cubellis, M. V. (2023) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-023-02852-w · Cited by 21
“[35, 36, 37] Protein N-glycosylation: • MPI-CDG Phosphomannose isomerase Sugar supplementation therapy Mannose provided by the diet becomes the only source of mannose 6-phosphate”
BackgroundScreening for "Prelysosomal Disorders": Carbohydrate-Deficient Glycoprotein Syndromes
Patterson, M. C. (1999) · Journal of Child Neurology · doi:10.1177/0883073899014001041 · Cited by 17
Mention, K., Michaud, L., Dobbelaere, D., Guimber, D., Gottrand, F., & Turck, D. (2001) · Archives of Disease in Childhood Fetal & Neonatal · doi:10.1136/fn.85.3.f217 · Cited by 17
Carbohydrate Systems in Targeted Drug Delivery: Expectation and Reality
Shchegravina, E. S., Sachkova, A. A., Usova, S. D., Nyuchev, A. V., Gracheva, Y. A., & Fedorov, A. Y. (2021) · Russian Journal of Bioorganic Chemistry · doi:10.1134/s1068162021010222 · Cited by 17
Mannose: A Promising Player in Clinical and Biomedical Applications
Chen, S., Wang, K., & Wang, Q. (2024) · Current Drug Delivery · doi:10.2174/0115672018275954231220101637 · Cited by 16
A Six-month-old infant with liver steatosis
Stormon, M., Cutz, E., Furuya, K. N., Bedford, M., Yerkes, L., Tolan, D. R., & Feigenbaum, A. J. (2004) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2003.11.037 · Cited by 18
Higashidani, A., Bode, L., Nishikawa, A., & Freeze, H. H. (2009) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.12.005 · Cited by 16
Self-citationEklund, E. A., & Freeze, H. H. (2005) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2005.11.001 · Cited by 22
Self-citationMariño, T. C., Leblanc, J., Pratte, A., Tardif, J., Thomas, M., Fortin, C., Girard, L., & Bouchard, L. (2023) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.63147 · Cited by 25
Treatment of congenital disorders of glycosylation: An overview
Quelhas, D., & Jaeken, J. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108567 · Cited by 19
Congenital disorder of glycosylation Ic due to a de novo deletion and an hALG-6 mutation
Eklund, E. A., Sun, L., Yang, S. P., Pasion, R. M., Thorland, E. C., & Freeze, H. H. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.073 · Cited by 18
Self-citationBahena-Bahena, D., López‐Valdez, J., Raymond, K., Salinas-Marín, R., Ortega-García, A., Ng, B. G., Freeze, H. H., Ruíz-Garcìa, M., & Martínez-Duncker, I. (2014) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2014.04.003 · Cited by 15
“The gel was washed overnight with physiological saline, fixed, stained with Coomassie Brilliant Blue R-250, destained, dried, and photographed [9].”
MethodSelf-citationEffects of Saccharides on Brain Function and Cognitive Performance
Best, T., Kemps, E., & Bryan, J. (2005) · Nutrition Reviews · doi:10.1111/j.1753-4887.2005.tb00115.x · Cited by 15
Intracranial Hemorrhage as the Initial Manifestation of a Congenital Disorder of Glycosylation
Cohn, R. D., Eklund, E. A., Bergner, A. L., Casella, J. F., Woods, S., Althaus, J., Blakemore, K. J., Fox, H. E., Hoover-Fong, J. E., Hamosh, A., et al. (2006) · PEDIATRICS · doi:10.1542/peds.2005-1307 · Cited by 15
Self-citationNakajima, K., Kizuka, Y., Yamaguchi, Y., Hirabayashi, Y., Takahashi, K., Yuzawa, Y., & Taniguchi, N. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.173 · Cited by 16
“Symptoms are relieved, becausemannose can be converted to GDPMan [10].”
BackgroundColomé, C., Ferrer, I., Artuch, R., Vilaseca, M. A., Pineda, M., & Briones, P. (2000) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2000.143 · Cited by 14
Calvo, P. L., Pagliardini, S., Baldi, M., Pucci, A., Sturiale, L., Garozzo, D., Vinciguerra, T., Barbera, C., & Jaeken, J. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-1004-9 · Cited by 14
“_) on articles by Jaeken et al (1998), de Koning et al (1998) and Niehues et al (1998) has made hepatologists wonder whether hepatic fibrosis might be due to a glycosylation defect.”
BackgroundSchnaar, R. L., & Freeze, H. H. (2007) · Glycobiology · doi:10.1093/glycob/cwm098 · Cited by 14
“However, except for rare patients with certain types of congenital disorders of glycosylation (CDG) (Niehues et al. 1998), the inference that humans can benefit clinically from ingesting these monosaccharides is unsupported by controlled clinical trials.”
BackgroundInfluentialSelf-citationDevelopmental and Inherited Liver Disease
Quaglia, A., Roberts, E. A., & Torbenson, M. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-7020-6697-9.00003-0 · Cited by 20
“1218, 1219 Histopathological features in the liver in CDGS appear to be nonspecific.”
Stormon, M., Mitchell, J. D., Smoleniec, J., Tobias, V., & Day, A. S. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200211000-00020 · Cited by 14
Hanßke, B., Thiel, C., Lübke, T., Hasilik, M., Höning, S., Peters, V., Heidemann, P. H., Hoffmann, G. F., Berger, E. G., FIGURA, K. V., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200214010 · Cited by 14
Self-citationCorrection of Leukocyte Adhesion Deficiency Type II With Oral Fucose
Marquardt, T., Lühn, K., Srikrishna, G., Freeze, H. H., Harms, E., & Vestweber, D. (1999) · Blood · doi:10.1182/blood.v94.12.3976.424k06_3976_3985 · Cited by 14
Self-citationDefecto congénito de glucosilación tipo Ib. Experiencia en el tratamiento con manosa
Hernández, E., Pajares, A. I. V., González, B. P., Crespo, M. J. E., Pérez, F. L., López-Manzanares, J. M., Pérez, M. U., & Silvestre, C. P.-C. (2008) · Anales de Pediatría · doi:10.1157/13126562 · Cited by 13
Carbohydrate‐deficient glycoprotein syndrome 1b: A new answer to an old diagnostic dilemma
Kelly, D., Boneh, A., Pitsch, S., Gold, H., Fietz, M., Nelson, P., & Oliver, M. (2001) · Journal of Paediatrics and Child Health · doi:10.1046/j.1440-1754.2001.00671.x · Cited by 13
Lectin analyses of glycoprotein hormones in patients with congenital disorders of glycosylation
Ferrari, M., Parini, R., Rocco, M. D., Radetti, G., Beck‐Peccoz, P., & Persani, L. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440409 · Cited by 13
Deeb, A., & Amoodi, A. A. (2018) · Clinical Case Reports · doi:10.1002/ccr3.1387 · Cited by 13
“Oral administration of mannose was found to be an effective therapy for CDG Ib as it corrected the clinical phenotype as well as the hypoglycosylation of serum glycoproteins [4].”
BackgroundMiller, B. S., Duffy, M. M., Addo, O. Y., & Sarafoglou, K. (2013) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709613503316 · Cited by 17
McKenzie, F. A., Fietz, M., Fletcher, J. M., Smith, R. L., Wright, I. M. R., & Jaeken, J. (2007) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.31867 · Cited by 13
“Joint contractures are a relatively uncommon finding in CDG, although fetal hydrops (CDG-Ia) and protein-losing enteropathy (CDG-Ib) are well recognized.”
BackgroundInfluentialToward a Molecular Understanding of Complex Childhood Enteropathies
MURCH, S. H. (2002) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/00005176-200205001-00002 · Cited by 14
The novel transferrin E592A variant impairs the diagnostics of congenital disorders of glycosylation
Park, J. H., Zühlsdorf, A., Wada, Y., Roll, C., Rust, S., Chesne, I. D., Grüneberg, M., Reunert, J., & Marquardt, T. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.05.011 · Cited by 12
Self-citationTamminga, R. Y. J., Lefeber, D. J., Kamps, W. A., & van Spronsen, F. J. (2008) · Pediatric Hematology and Oncology · doi:10.1080/08880010802394616 · Cited by 12
“656G>A (R129Q), which has been described before [5].”
BackgroundIt Is Not Always Alcohol Abuse—A Transferrin Variant Impairing the CDT Test
Zühlsdorf, A., Said, M., Seger, C., Park, J. H., Reunert, J., Rust, S., Wada, Y., Grüneberg, M., Chesne, I. D., & Marquardt, T. (2015) · Alcohol and Alcoholism · doi:10.1093/alcalc/agv099 · Cited by 14
“To detect mass changes in the Tf molecule immunoprecopitation and SDS-Page were performed according to the previously described method (Niehues et al., 1998).”
MethodSelf-citationTreatment: Present Status and New Trends
Walter, J. H., & Wraith, J. E. (2006) · Springer eBooks · doi:10.1007/978-3-540-28785-8_5 · Cited by 11
Determination of d-Mannose in Serum by Capillary Electrophoresis
Carchon, H. A., & Jaeken, J. (2001) · Clinical Chemistry · doi:10.1093/clinchem/47.7.1319 · Cited by 12
Knopf, C. F., Rod, R., Jaeken, J., Berant, M., SCHAFTINGEN, E. V., Fryns, J. P., Brill‐Zamir, R., Gershoni‐Baruch, R., Lischinsky, S., & Mandel, H. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005612120886 · Cited by 12
“Based on the IEF patterns and the clinical symptoms, Ðve di†erent types have been classiÐed so far (for references see Jaeken et al 1997 ; Niehues et al 1998).”
BackgroundMethodSyndrome d'hypoglycosylation des glycoprotéines sériques
de Lonlay, P., Cormier‐Daire, V., Vuillaumier‐Barrot, S., Cuer, M., Durand, G., Münnich, A., Saudubray, J., & Séta, N. (2000) · Archives de Pédiatrie · doi:10.1016/s0929-693x(00)88089-6 · Cited by 14
Huemer, M., Huber, W., Schima, W., Möeslinger, D., Holzbach, U., Wevers, R. A., Wank, H., & Stoeckler-Ipsiroglu, S. (2000) · The Journal of Pediatrics · doi:10.1067/mpd.2000.105130 · Cited by 12
Manipulating mannose metabolism as a potential anticancer strategy
Harada, Y. (2024) · FEBS Journal · doi:10.1111/febs.17230 · Cited by 12
“1) and improves many, if not all, symptoms [42].”
InfluentialLuo, J., Wu, T., Zhang, J., Liang, Z., Shao, W., Wang, D., Li, L., Zuo, D., & Zhou, J. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01070-3 · Cited by 13
Clinical utility gene card for: Phosphomannose isomerase deficiency
Jaeken, J., Lefeber, D. J., & Matthijs, G. (2014) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.29 · Cited by 10
Genetic Diseases Associated with Protein Glycosylation Disorders in Mammals
Nakayama, Y., Nakamura, N., Tsuji, D., Ito, K., & Kurosak, A. (2013) · InTech eBooks · doi:10.5772/54097 · Cited by 15
“Interestingly, it was found that treating patients with CDG-Ib, but not CDG-Ia, with high-mannose diet alleviates the clinical manifestation, since mannose 6-phospahte can be produced by hexokinase from mannose ingested from food [7].”
BackgroundAlteration of glycan structures by swainsonine affects steroidogenesis in bovine luteal cells
Sano, M., Hashiba, K., Higashi, M., & Okuda, K. (2015) · Theriogenology · doi:10.1016/j.theriogenology.2015.05.026 · Cited by 10
Is There Treatment for “Genetic” Disease?
Scriver, C. R., & Treacy, E. P. (1999) · Molecular Genetics and Metabolism · doi:10.1006/mgme.1999.2907 · Cited by 10
Yang, H., Han, N., Luo, Z., Xu, J., Guo, L., & Liu, Y. F. (2022) · Journal of Periodontology · doi:10.1002/jper.22-0294 · Cited by 10
Mühlhausen, C., Henneke, L., Schlotawa, L., Behme, D., Grüneberg, M., Gärtner, J., & Marquardt, T. (2020) · JIMD Reports · doi:10.1002/jmd2.12149 · Cited by 8
“It has been described that coagulation abnormalities resolve within weeks after beginning mannose supplementation, and no thromboses have been described in MPICDG patients on mannose therapy.(3,6,8) This is in line with observation of the patient presented here, in which AT activity normalized within 2 weeks after ini…”
BackgroundResultSelf-citationMarlen, G., Panagiotou, E., Himmelreich, N., Hüllen, A., Beedgen, L., Dimitrov, B., Geiger, V., Zielonka, M., Peters, V., Strahl, S., et al. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100673 · Cited by 10
Nguan, H.-S., Ishak, K. A., Zahid, N. I., Martínez-Felipe, A., Hashim, R., & Aripin, N. F. K. (2022) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2022.119027 · Cited by 8
Congenital Disorders of Glycosylation
Jaeken, J., & van den Heuvel, L. (2014) · Springer eBooks · doi:10.1007/978-3-642-40337-8_30 · Cited by 8
Neurometabolic and neurodegenerative diseases in children
Radke, J., Stenzel, W., & Goebel, H. H. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00009-2 · Cited by 9
The congenital disorders of glycosylation: A multifaceted group of syndromes
Eklund, E. A., & Freeze, H. H. (2006) · Neurotherapeutics · doi:10.1007/bf03207055 · Cited by 11
Self-citationMPI‐CDG from a hepatic perspective: Report of two Egyptian cases and review of literature
Ghaffar, T. Y. A., Ng, B. G., Elsayed, S. M., Naghi, S. E., Helmy, S., Mohammed, N. M., Hennawy, A. E., & Freeze, H. H. (2020) · JIMD Reports · doi:10.1002/jmd2.12159 · Cited by 10
“The enzymatic and molecular basis of MPI-CDG was described by.(5) So far, only 35 patients with MPI-CDG have been described in the literature.”
BackgroundSelf-citationMURCH, S. H. (2001) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/s1052-5157(18)30045-x · Cited by 8
Our Experience with Diagnostics of Congenital Disorders of Glycosylation
Albahri, Z., Marklová, E., Vaníček, H., Minxová, L., Dědek, P., Skálová, S., Talábová, M., Vávrová, J., & Rencová, E. (2004) · Acta Medica (Hradec Kralove Czech Republic) · doi:10.14712/18059694.2018.103 · Cited by 8
New Insights on Sperm Function in Male Infertility of Unknown Origin: A Multimodal Approach
Pacheco, R. I., Cristo, M. I., Anjo, S. I., Silva, A. F., Sousa, M. I., Tavares, R. S., Sousa, A. P., Almeida‐Santos, T., Moura‐Ramos, M., Caramelo, F. J., et al. (2023) · Biomolecules · doi:10.3390/biom13101462 · Cited by 10
“…rearrangements [64,65], acrosome reaction [56], gamete interaction, fertilization process [54,55,63], and also metabolism (especially glucose metabolism) [57,58,147], mitochondrial function [50] and oxidative stress [51] and might also play a role on spermatogenesis [57,61,62,68,69] (Table 3).”
Backgroundden Hollander, B., Brands, M. M. M. G., de Boer, L., Haaxma, C. A., Lengyel, A., van Essen, P., Peters, G., Kwast, H. J. T., Klein, W. M., Coene, K. L. M., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12643 · Cited by 7
Lehle, L., Strahl, S., & Tanner, W. (2006) · Angewandte Chemie · doi:10.1002/ange.200601645 · Cited by 8
Gressner, O. A., Jafari, S., Erkens, M., Gao, C., Stanzel, S. F., & Gressner, A. M. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.02.017 · Cited by 7
Congenital disorders of glycosylation type Ia and Ib. Genetic, biochemical and clinical studies.
Kjærgaard, S. (2004) · PubMed · Cited by 12
Biliary Atresia and Neonatal Disorders of the Bile Ducts
Mieli‐Vergani, G., & Hadžić, N. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4377-0774-8.10069-7 · Cited by 7
Kemme, L., Grüneberg, M., Reunert, J., Rust, S., Park, J. H., Westermann, C., Wada, Y., Schwartz, O., & Marquardt, T. (2021) · JIMD Reports · doi:10.1002/jmd2.12213 · Cited by 8
“In some, monosaccharide or cofactor supplementation have been shown to exert favorable effects on both glycosylation and clinical presentation.(20,41-47) To date, there is no therapeutic approach to treat MAN1B1-CDG.”
BackgroundMethodSelf-citationBubel, S., Peters, V., Klein, C., Hackler, R., Schaefer, J. R., Hagenah, J., Hoffmann, G. F., & Vieregge, P. (2002) · Der Nervenarzt · doi:10.1007/s00115-002-1351-y · Cited by 7
Aoki, E., Manabe, N., Ohno, S., Aoki, T., Furukawa, J., Togayachi, A., Aoki-Kinoshita, K. F., Inokuchi, J., Kurosawa, K., Kaname, T., et al. (2023) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2023.101016 · Cited by 7
Rescuing Lethal Phenotypes Induced by Disruption of Genes in Mice: a Review of Novel Strategies
Lipták, N., Gál, Z., Biró, B., Hiripi, L., & Hoffmann, O. I. (2021) · Physiological Research · doi:10.33549/physiolres.934543 · Cited by 7
Diseases Associated with Carbohydrates/Glycoconjugates*
Eklund, E. A., Bode, L., & Freeze, H. H. (2007) · Elsevier eBooks · doi:10.1016/b978-044451967-2/00098-2 · Cited by 8
Self-citationCongenital Disorders of Glycosylation
Jaeken, J. (2006) · Springer eBooks · doi:10.1007/3-540-28962-3_22 · Cited by 6
Dupré, T., Ogier‐Denis, É., Moore, S. E. H., Cormier‐Daire, V., Dehoux, M., Durand, G., Séta, N., & Codogno, P. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(99)00009-5 · Cited by 6
Defectos congénitos de la glucosilación: últimos avances y experiencia española
Vilaseca, M. A., Artuch, R., & Briones, P. (2004) · Medicina Clínica · doi:10.1016/s0025-7753(04)74362-6 · Cited by 6
Propuesta de protocolo de estudio de las enfermedades cerebrovasculares de la infancia
Jalón, E. C., Marfà, M. P., Iriberri, R. A., Buscà, M. A. V., & Plana, J. C. (2000) · Anales de Pediatría · doi:10.1016/s1695-4033(00)77376-0 · Cited by 6
“Anemia 15 (22) Estados de hipercoagulabilidad Trombocitosis* 3 (5,1) Alteración coagulación básica 5 (7,3) Déficit proteína S 5 (7,3) Déficit proteína C 8 (11,7) Antitrombina III** 5 (11,7) APL (transitoria) 5 (7,3)”
BackgroundMpi-driven N-glycosylation orchestrates mucin O-glycosylation and intestinal homeostasis
Roy, A., Meregini, S., Cho, H.-J., Chen, Z., Zaki, A., Argula, T., Beutler, B., & SoRelle, J. A. (2026) · Nature Communications · doi:10.1038/s41467-026-73100-5 · Cited by 6
“In humans, MPI-CDG is very rare ( 1:1,000,000) 9 and characterized by protein-losing enteropathy (PLE), chronic diarrhea, cirrhosis, cyclic vomiting, anemia, and hyperinsulinemic hypoglycemia 10,11 .”
Congenital Diarrhoeas and Enteropathies
Köglmeier, J., & Lindley, K. J. (2024) · Nutrients · doi:10.3390/nu16172971 · Cited by 5
“The disorder has been successfully treated with oral mannose supplementation, with improvements in both diarrhoea and liver function [31].”
Background
Metadata
- Authors
- Niehues, R., Hasilik, M., Alton, G., Körner, C., Schiebe-Sukumar, M., Koch, H. G., Zimmer, K. P., Wu, R., Harms, E., Reiter, K., von Figura, K., Freeze, H. H., Harms, H. K., & Marquardt, T.
- Affiliations
- University Hospital Münster (DE)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of Göttingen (DE)
- Venue
- Journal of Clinical Investigation
- Published
- 1998-04-01
- Volume
- 101
- Issue
- 7
- Pages
- 1414-1420
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC508719
- OpenAlex
- W1970122244
- Cited by
- 422
- References
- 20
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 13 · 2023: 11 · 2022: 8 · 2021: 14 · 2020: 16 · 2019: 7 · 2018: 12 · 2017: 12 · 2016: 4 · 2015: 13 · 2014: 18 · 2013: 7 · 2012: 14
- FWCI
- 22.32
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01gm049096-04)
- National Institute of General Medical Sciences (R01 GM49096)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- protein-losing enteropathy, phosphomannomutase deficiency
- MeSH terms
- Cells, Cultured, Glycoproteins, Glycosylation, Humans, Infant, Male, Mannose, Mannose-6-Phosphate Isomerase, Mutation, Protein Processing, Post-Translational, Protein-Losing Enteropathies, Syndrome, Transferrin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.